Skip to main content
CivicGate

HR 6130
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

ASAP Act

To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.

Introduced Nov 19, 2025

Latest action (Nov 19, 2025) Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Referred to
Ways and Means Committee Energy and Commerce Committee
Policy area
Health

Summary

This bill amends Medicare to cover blood-based screening tests for Alzheimer's disease and related dementias, starting January 1, 2028. The covered tests include genomic sequencing blood tests and other approved biomarker tests that detect early or pre-symptomatic stages of Alzheimer's disease or related dementias. Tests must be cleared, classified, or approved by the FDA. The Secretary of Health and Human Services may determine that other equivalent tests, such as those using protein analysis or whole genome sequencing, are appropriate for coverage if they provide comparable results.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
193 cosponsors

Money behind the sponsor

Top reported contributors to Vern Buchanan’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • SELECT MEDICAL CORPORATION $43,200
  • FLORIDA CRYSTALS $16,100
  • DERICK DERMATOLOGY $13,200
  • BLACKSTONE $8,100
  • CASL $7,609

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Vern Buchanan → · Outside spending →

Actions (2)
  1. Nov 19, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
  2. Nov 19, 2025 Introduced in House

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • S 3267 — ASAP Act · Introduced Nov 20, 2025 · Cong. 119 89%
  • HR 9061 — PREEMPT Act · Introduced May 29, 2026 · Cong. 119 65%
  • S 2761 — RESULTS Act · Introduced Sep 10, 2025 · Cong. 119 64%
  • HR 8260 — Cardiovascular Disease Early Detection and Prevention Act of 2026 · Introduced Apr 14, 2026 · Cong. 119 63%
  • HR 6799 — BRIDGE for Young-Onset Alzheimer’s Disease Act of 2025 · Introduced Dec 17, 2025 · Cong. 119 62%
  • HR 6320 — Improving Medicaid Precision and Cancer Test Act of 2025 · Introduced Nov 28, 2025 · Cong. 119 62%

Text versions (1)
  • Introduced in House · Nov 19, 2025

Only one text version is on file, so there’s no earlier version to compare against yet.

Full text

IN THE HOUSE OF REPRESENTATIVES

November 19, 2025

Mr. Buchanan (for himself and Mr. Tonko) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Alzheimer’s Screening and Prevention Act of 2025” or the “ASAP Act”.

SEC. 2. MEDICARE COVERAGE OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS EARLY DETECTION SCREENING TESTS.

(a) Coverage.—Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended—

(1) in subsection (s)(2)—

(A) in subparagraph (JJ), by striking the semicolon at the end and inserting “; and”; and

(B) by adding at the end the following new subparagraph: “(KK) Alzheimer’s disease and related dementias early detection screening tests (as defined in subsection (nnn));”; and

(2) by adding at the end the following new subsection: “(nnn) Alzheimer’s Disease and Related Dementias Early Detection Screening Tests.—The term ‘Alzheimer’s disease and related dementias early detection screening test’ means a test furnished to an individual for the detection of the pre-symptomatic and early stage of Alzheimer’s disease or related dementias on or after January 1, 2028, that—

“(1) is cleared under section 510(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and

“(2) is—

“(A) a genomic sequencing blood or blood product test; or

“(B) such other equivalent test, including a single-analyte test, blood test analysis of cell-free nucleic acids, multiplex panel test, whole genome sequencing, protein expression, whole exome, whole transcriptome, and medical imaging (which are based on blood, blood products, tissue, urine or other biospecimen), as the Secretary determines appropriate in providing results comparable to those obtained with a test described in subparagraph (A).”.

(b) Payment.—Section 1833(h)(1)(A) of the Social Security Act (42 U.S.C. 1395l(h)(1)(A)) is amended by inserting “Alzheimer’s disease and related dementias early detection screening tests under section 1861(nnn) and” after “including”. <all>

Comments

Comments

Loading comments…